Category: 1662-01-7

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1662-01-7,4,7-Diphenyl-1,10-phenanthroline,as a common compound, the synthetic route is as follows.

General procedure: The pentafluorinated beta-diketone ligand (3 mmol), NaOH(0.12 g, 3 mmol) and the auxiliary ligand (1 mmol) were dissolved in 30 mL ethanol and heated to 60 C under stirring. Then, the ethanolic solution of EuCl3¡¤6H2O(1 mmol) was added dropwise, and the reaction mixture was stirred at 60 C for 8 h. After cooling down, the yellow solid was precipitated and filtered off. The solidproduct was washed with deionized water and ethanol, and dried in vacuum. Yellow powder, yield 78%, mp 200-202 C; IR nu (KBr):3031(m), 2967 (m), 2843 (w), 1597 (s), 1572 (s), 1501 (s), 1258 (s), 1172 (s),1082 (m), 1013 (m), 930 (m), 845 (m), 789 (s), 588 (m), 508 (m) cm-1; 1H NMR(300 MHz, CDCl3):delta 3.70 (s, 3H, C=CH), 3.94 (s, 9H, OCH3),6.86 (br, 6H, Ar-H),7.61 (br, 6H, Ar-H), 7.96 (br, 2H, Bath-H), 8.17 (br, 4H, Bath-H), 8.58 (br, 2H,Bath-H), 8.73 (br, 4H, Bath-H), 9.24 (br, 2H, Bath-H), 12.10 (br, 2H, Bath-H) ppm.Anal. Calcd. for EuC60H40N2O9F15:C, 52.61; H, 2.94; N, 2.04; Eu, 11.09; Found C,52.94; H, 2.91; N, 2.09; Eu, 11.25.

The synthetic route of 1662-01-7 has been constantly updated, and we look forward to future research findings.

Reference£º
Article; Wan, Yupeng; Lyu, Heng; Du, Hengyi; Wang, Dunjia; Yin, Guodong; Research on Chemical Intermediates; vol. 45; 4; (2019); p. 1669 – 1687;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1662-01-7,4,7-Diphenyl-1,10-phenanthroline,as a common compound, the synthetic route is as follows.

General procedure: The copper-phosphine complex (1.00 mmol) together with 10.0 ml of CHCl3 is placed in a Schlenk vessel. The phosphine (1.00 mmol) is added to this solution until it is completely dissolved. A solution of the N-ligand (1.00 mmol) in 2 ml of CHCl3 is then added over a period of 30 minutes. The mixture is subsequently stirred at room temperature for a further 30 minutes. After removal of the CHCl3 in vacuo, the resulting solid is recrystallized from CH2Cl2 and Et2O.Example 50 (4,7-diphenyl-1,10-phenanthroline)bis(triphenylphosphine)copper(I) nitrate (4,7-Diphenyl-1,10-phenanthroline)bis(triphenylphosphine)copper(I) nitrate was prepared from bis(triphenylphosphine)copper(I) nitrate (650 mg, 1.00 mmol), 4,7-diphenyl-1,10-phenanthroline (339 mg, 1.00 mmol) and triphenylphosphine (262 mg, 1.00 mmol). This gives (4,7-diphenyl-1,10-phenanthroline)bis(triphenylphosphine)copper(I) nitrate (980 mg, 99%) as a yellow solid. 31P NMR (162 MHz, CDCl3) delta=3.32 (s, 1P) ppm. Anal. calc. for C48H36Cl2CuN3O3P2: C, 59.8, H, 3.9, N, 4.3. Found: C, 59.0, H, 3.8, N, 4.6.

The synthetic route of 1662-01-7 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; BASF SE; Goossen, Lukas J; Rodriguez Garrido, Nuria; Manjolinho Costa, Filipe; Lange, Paul P.; US2014/12000; (2014); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1662-01-7,4,7-Diphenyl-1,10-phenanthroline,as a common compound, the synthetic route is as follows.

(NEt4)[OsNCl4] (50 mg, 0.85 mmol) was dissolved in 2 mL of acetone. To this, a solution of 4,7-diphenyl- I, 10-phenanthroline (85 mg, 2,55 mmol) in dichloromethane (5 mL) was added in a dropwise manner. The combined solutions were stirred at room temperature for 24 h. The resultant precipitate was filtered and washed with warm acetone, dichloromethane and diethyl ether. The osmium(VI) nitrido complex was isolated as a purple powder. Yield: 15 mg (27%). 1H NMR (400 MHz, DMSO-d6): delta 9.63 (d, 1H), 8.99 (d, 1H), 8.24 (m, 3H), 8.09 (d, 1H), 7.85 (m, 2H), 7.70 (m, 8H). 13C NMR (400 MHz, DMSO-d6): delta 156.2, 154.9, 151.7, 148.8, 144.5, 141.3, 135.5, 134.7, 134.2, 130.8, 130.5, 130.3, 129.7, 129.7, 129.2, 128.1, 128.1, 127.4, 126.7, 126.4. IR (KBr, cm”1): 1080.5 (OsN). Anal. Calcd. for 3, C24H16N30sCl3: C, 44.83; H, 2.51; N, 6.54. Found: C, 44.51; H, 2.27; N, 6.32.

1662-01-7 4,7-Diphenyl-1,10-phenanthroline 72812, acatalyst-ligand compound, is more and more widely used in various.

Reference£º
Patent; MASSACHUSETTS INSTITUTE OF TECHNOLOGY; LIPPARD, Stephen, J.; SUNTHARALINGAM, Kogularamanan; (101 pag.)WO2016/4156; (2016); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1662-01-7,4,7-Diphenyl-1,10-phenanthroline,as a common compound, the synthetic route is as follows.

0.34 mmol dichloro bridged intermediate and 1.0 g4,7-diphenyl-1,10-phenanthroline was dissolved in 40 mL of ethylene glycol.The reaction system is protected with nitrogen.Stirred at 130 C for 15 hours.After cooling to room temperature, the reaction solution was poured into a 100 mL flask.A saturated NH4PF6 aqueous solution was added thereto with stirring.A large amount of solids precipitated,filter,Wash with a small amount of deionized water,70 C vacuum drying for 5 hours,The crude product is chromatographed on a chromatographic column.a dark brown solidYield 50%.

As the paragraph descriping shows that 1662-01-7 is playing an increasingly important role.

Reference£º
Patent; Tsinghua University; Qiao Juan; Xin Lijun; (29 pag.)CN104804045; (2018); B;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI